6500 Stock Overview
A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
OpGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.57 |
| 52 Week High | US$3.55 |
| 52 Week Low | US$1.42 |
| Beta | -0.60 |
| 11 Month Change | 0% |
| 3 Month Change | -3.74% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -55.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6500 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | 0.8% |
| 1Y | n/a | -18.3% | 8.6% |
Return vs Industry: Insufficient data to determine how 6500 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 6500 performed against the German Market.
Price Volatility
| 6500 volatility | |
|---|---|
| 6500 Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6500's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 6500's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 93 | John Tan | www.opgen.com |
OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company’s products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services.
OpGen, Inc. Fundamentals Summary
| 6500 fundamental statistics | |
|---|---|
| Market cap | €14.80m |
| Earnings (TTM) | -€9.47m |
| Revenue (TTM) | €1.21m |
12.2x
P/S Ratio-1.6x
P/E RatioIs 6500 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6500 income statement (TTM) | |
|---|---|
| Revenue | US$1.27m |
| Cost of Revenue | US$1.59m |
| Gross Profit | -US$323.88k |
| Other Expenses | US$9.59m |
| Earnings | -US$9.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | -25.59% |
| Net Profit Margin | -783.50% |
| Debt/Equity Ratio | 0% |
How did 6500 perform over the long term?
See historical performance and comparison